News
AUTL
6.38
+2.24%
0.14
Autolus Therapeutics Plc Files For Resale Of Up To 33.33M Shares By The Selling Securityholder
Benzinga · 15h ago
Weekly Report: what happened at AUTL last week (0318-0322)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Etao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health stock rose 42.96% and SCWorx stock increased by 14.08% in the same session.
Benzinga · 03/20 13:05
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company has an average price target of $9.0. 4 analysts have expressed a variety of opinions on AutolusTherapeutics over the past quarter. The 12-month price targets assessed by analysts have increased by 9.09% to $8.25.
Benzinga · 03/18 16:01
Autolus Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 03/18 13:56
Autolus Therapeutics Price Target Raised to $10.00/Share From $9.00 by Truist Securities
Dow Jones · 03/18 13:56
Weekly Report: what happened at AUTL last week (0311-0315)?
Weekly Report · 03/18 09:12
12 Health Care Stocks Moving In Friday's After-Market Session
Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. Aclarion and SCWorx stock rose by 10.39% and 7.55% respectively.
Benzinga · 03/15 21:33
Buy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-cel
TipRanks · 03/15 09:16
Autolus Therapeutics Price Target Maintained With a $9.00/Share by Needham
Dow Jones · 03/14 19:38
Autolus Therapeutics Is Maintained at Buy by Needham
Dow Jones · 03/14 19:38
Needham Maintains Buy on Autolus Therapeutics, Maintains $9 Price Target
Benzinga · 03/14 19:28
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
TipRanks · 03/14 17:40
Autolus Therapeutics Announces Annual Results and CDO Resignation
TipRanks · 03/14 16:42
Autolus Therapeutics GAAP EPS of -$1.20 misses by $0.10, revenue of $1.69M misses by $0.01M
Seeking Alpha · 03/14 11:02
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Pre-Market Earnings Report for March 14, 2024 : DG, DKS, BEKE, WB, GIII, CSIQ, MOMO, AUTL, PHAR, URGN, AVAH, BBW
NASDAQ · 03/13 20:00
Autolus Therapeutics FY 2023 Earnings Preview
Seeking Alpha · 03/13 16:32
Autolus Therapeutics's Earnings Outlook
Autolus Therapeutics is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.25. Last quarter the company missed EPS by $0.01. The company's shares are up 150.47% over the last 52 weeks.
Benzinga · 03/13 16:00
BUZZ-J&J, 2seventy bio fall after US FDA raises concerns over CAR-T therapy data
US FDA raises concerns over CAR-T therapy data. Shares of Johnson & Johnson drop as much as 1.8%, while 2seventy bio TSVT.O slumps 11.7%. FDA staff reviewers say it is unclear if cancer cell therapies by J&J would benefit blood cancer patients.
Reuters · 03/13 14:52
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.